Evinacumab reduced LDL cholesterol by a mean of 49% (absolute change of -157 mg/dL) at 4 weeks in adults with homozygous familial hypercholesterolemia.
Does evinacumab reduce LDL cholesterol in adults with homozygous familial hypercholesterolemia?
Evinacumab substantially reduces LDL cholesterol in patients with homozygous familial hypercholesterolemia.
Absolute Event Rate: 0% vs 0%
Evinacumab, a monoclonal antibody that blocks ANGPTL3, was administered to nine adults with homozygous familial hypercholesterolemia. At 4 weeks, LDL cholesterol was reduced by a mean of 49%, with a mean absolute change from baseline of −157 mg per deciliter.
Gaudet et al. (Wed,) reported a other. Evinacumab reduced LDL cholesterol by a mean of 49% (absolute change of -157 mg/dL) at 4 weeks in adults with homozygous familial hypercholesterolemia.